Oliver Wyman Actuarial Consulting analyzes what happens after manufacturer costs for brand drugs change hands.
Based on our analysis recently featured in the Wall Street Journal, the prevalence of no cost bronze coverage has increased significantly for 2018.
Using comparative data to curb overprescribing and control the opioid epidemic.
With repeal and replace on pause, the reform spotlight is shifting to 1332 waivers, which give states the ability to waive some provisions of the ACA. A detailed look at the waiver process, state interest, and how health insurers might be impacted.
Oliver Wyman research reveals that majority of health insurers surveyed remain committed to the ACA exchanges, but with some tweaks and continued watchfulness.
A look inside our policy brief urging legislators to consider the impact of health reform on US employers and the 177 million people who receive health coverage from them.
A side-by-side comparison of the leading repeal-and-replace proposals.
Despite changing political winds, value-based initiatives are as relevant as ever. Read new analysis of the ACO market and insight into next, best moves.
What does a Trump presidency mean for healthcare organizations? Must-read articles from Oliver Wyman Health.
Through this series of infographics, learn how payers, providers, and life sciences companies will be impacted by our 45th president.
